Synthesis and anti-proliferative activity evaluation of N3-acyl-N5-aryl-3,5-diaminoindazole analogues as anti-head and neck cancer agent
Tóm tắt
Head and neck squamous cell carcinoma (HNSCC) is the 11th leading cancer by incidence worldwide. Surgery and radiotherapy have been the major treatment for patients with HNSCC while chemotherapy has become an important treatment option for locally advanced HNSCC. Understanding of the molecular mechanisms underlying HNSCC impelled the development of targeted therapeutic agents. The development and combinations of targeted therapies in different cellular pathways may be needed to fulfill the unmet needs of current HNSCC chemotherapy. A series of N 3-acyl-N 5-aryl-3,5-diaminoindazoles were synthesized and their anti-proliferative activities were evaluated against human cancer cell lines, Caki, A549, AMC-HN1, AMC-HN3, AMC-HN4, AMC-HN6, and SNU449. The cellular selectivity of compound was obtained by the modification of substituent at N 5-aryl group of 3,5-diaminoindazole. Compound 9a and 9b showed more than 7-fold selectivity for AMC-HN4 and AMC-HN3, respectively. N 3-acyl-N 5-aryl-3,5-diaminoindazole analogues can be used as hits in the development of anticancer drug for HNSCC.
Tài liệu tham khảo
Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D: Global cancer statistics. CA Cancer J Clin. 2011, 61: 69-90. 10.3322/caac.20107.
Argiris A, Karamouzis MV, Raben D, Ferris RL: Head and neck cancer. Lancet. 2008, 371: 1695-1709. 10.1016/S0140-6736(08)60728-X.
Molinolo AA, Amornphimoltham P, Squarize CH, Castilho RM, Patel V, Gutkind JS: Dysregulated molecular networks in head and neck carcinogenesis. Oral Oncol. 2009, 45: 324-334. 10.1016/j.oraloncology.2008.07.011.
Tobias JS, Monson K, Gupta N, MacDougall H, Glaholm J, Hutchison I, Kadalayil L, Hackshaw A: Chemoradiotherapy for locally advanced head and neck cancer: 10-year follow-up of the UK Head and Neck (UKHAN1) trial. Lancet Oncol. 2010, 11: 66-74. 10.1016/S1470-2045(09)70306-7.
Le Tourneau C, Faivre S, Siu LL: Molecular targeted therapy of head and neck cancer: review and clinical development challenges. Eur J Cancer. 2007, 43: 2457-2466. 10.1016/j.ejca.2007.08.016.
Rao SD, Fury MG, Pfister DG: Molecular-targeted therapies in head and neck cancer. Semin Radiat Oncol. 2012, 22: 207-213. 10.1016/j.semradonc.2012.03.005.
Leemans CR, Braakhuis BJM, Brakenhoff RH: The molecular biology of head and neck cancer. Nat Rev Cancer. 2011, 11: 9-22. 10.1038/nrc2982.
Lee J, Choi H, Kim K-H, Jeong S, Park J-W, Baek C-S, Lee S-H: Synthesis and biological evaluation of 3,5-diaminoindazoles as cyclin-dependent kinase inhibitors. Bioorg Med Chem Lett. 2008, 18: 2292-2295. 10.1016/j.bmcl.2008.03.002.
Dai Y, Hartandi K, Ji Z, Ahmed AA, Albert DH, Bauch JL, Bouska JJ, Bousquet PF, Cunha GA, Glaser KB: Discovery of N-(4-(3-amino-1H-indazol-4-yl)phenyl)-N‘-(2-fluoro-5-methylphenyl)urea (ABT-869), a 3-aminoindazole-based orally active multitargeted receptor tyrosine kinase inhibitor. J Med Chem. 2007, 50: 1584-1597. 10.1021/jm061280h.
Medina JR, Blackledge CW, Heerding DA, Campobasso N, Ward P, Briand J, Wright L, Axten JM: Aminoindazole PDK1 inhibitors: a case study in fragment-based drug discovery. ACS Med Chem Lett. 2010, 1: 439-442. 10.1021/ml100136n.
Raffa D, Maggio B, Cascioferro S, Raimondi MV, Schillaci D, Gallo G, Daidone G, Plescia S, Meneghetti F, Bombieri G: Synthesis and antiproliferative activity of 3-amino-N-phenyl-1H-indazole-1-carboxamides. Eur J Med Chem. 2009, 44: 165-178. 10.1016/j.ejmech.2008.03.023.
Shin HC, Song DW, Baek WK, Lee SR, Kwon TK, Lee J, Park SH, Jang BC, Park JW: Anticancer activity and differentially expressed genes in head and neck cancer cells treated with a novel cyclin-dependent kinase inhibitor. Chemotherapy. 2009, 55: 353-362. 10.1159/000232450.
Papazisis KT, Geromichalos GD, Dimitriadis KA, Kortsaris AH: Optimization of the sulforhodamine B colorimetric assay. J Immunol Methods. 1997, 208: 151-158. 10.1016/S0022-1759(97)00137-3.
Kalish LH, Kwong RA, Cole IE, Gallagher RM, Sutherland RL, Musgrove EA: Deregulated cyclin D1 expression is associated with decreased efficacy of the selective epidermal growth factor receptor tyrosine kinase inhibitor gefitinib in head and neck squamous cell carcinoma cell lines. Clin Cancer Res. 2004, 10: 7764-7774. 10.1158/1078-0432.CCR-04-0012.
Park HW, Song SY, Lee TJ, Jeong D, Lee TY: Abrogation of the p16-retinoblastoma-cyclin D1 pathway in head and neck squamous cell carcinomas. Oncol Rep. 2007, 18: 267-272.
Åkervall J, Kurnit DM, Adams M, Zhu S, Fisher SG, Bradford CR, Carey TE: Overexpression of cyclin D1 correlates with sensitivity to cisplatin in squamous cell carcinoma cell lines of the head and neck. Acta Otolaryngol (Stockh). 2004, 124: 851-857. 10.1080/00016480410017323.